Public Health Agency of Canada
www.publichealth.gc.ca
Common menu bar links
Life with Arthritis in Canada : A personal and public health challenge
[Previous] [Table of Contents] [Next]
Chapter Seven: Arthritis-related prescription medication use
Table of Contents
" I have not had success with two biologics and a host of other drugs, but now am on one that is working very well for me. Most people would not even know I have a disease. I have had one hand surgery and was in line for a knee replacement until I started a medication that had basically put me into a remission."
— Person living with Still's disease
Introduction
Arthritis encompasses a group of complex diseases for which there is currently no known cure. Medication is a key component of the management of arthritis in the effort to reduce pain, maintain joint function and limit disease progression.1
For some types of arthritis, particularly inflammatory conditions, early diagnosis and timely treatment is vital in order to reduce pain and inflammation, prevent or reduce disability, and to improve overall quality of life.2 3 4 5 6 7 8 9 Without effective treatment, the course of many forms of arthritis such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) leads to functional disability.4 8
Currently, medications used for treating arthritis include: analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) and biologic response modifiers (also known as biologics). In recent years, the introduction of new drugs such as biologics, have greatly improved the efficacy of pharmacological treatment for arthritis. Furthermore, innovative drugs for osteoarthritis (OA) are on the horizon, including drugs to prevent the progression in the early stages of the disease and disease-modifying drugs for established OA (DMOADs).10
This chapter examines the use of arthritis-related medications by type of arthritis, age, sex, year and drug classes, using IMS Health Canada (IMS) data. The specific types of arthritis were grouped into five categories:
- Osteoarthritis (OA);
- Rheumatoid arthritis (RA);
- Other inflammatory arthritis (e.g. gout, psoriatic arthritis (PsA), ankylosing arthritis (AS));
- Connective tissue diseases (e.g. systemic lupus erythematosus, scleroderma); and
• Other arthritis conditions (e.g. polymyalgia rheumat- ica, tendonitis, bursitis, synovitis, internal derangement of the knee, other unspecified arthropathies).
Analgesics (pain medication)
Simple Analgesics include medications such as acetaminophen. While they are considered the first-line therapy for arthritis pain (predominately used in OA), they have no effect on inflammation.1 2 11 This form of pain medication does not require a prescription; as a result, it is difficult to track its usage.1 11
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are one of the most widely used medications in the treatment of arthritis because of their painkilling (especially acute pain) and anti-inflammatory properties.1 3 12 They are used in the treatment of most forms of arthritis, including OA, RA, gout, AS, PsA and connective tissue disorders.2 7 11 12 13 14 15 16 17 18 Some NSAIDs are available over-the-counter and some require a prescription from a physician.
Gastrointestinal (GI) protective agents
Best practice guidelines recommend that GI protective agents be prescribed to treat or prevent the GI complications (e.g. GI bleeding) associated with the use of NSAIDs among those who present with risk factors for GI problems, such as advanced age, multiple NSAIDs use or prior ulcer. GI protective agents are also prescribed for other conditions, such as Gastroesophageal Reflux Disease (GERD), primary gastro-duodenal ulcers and many stomach and bowel symptoms unrelated to the use of NSAIDs.19
Corticosteroids
Corticosteroids have successfully been used to reduce joint inflammation and disease activity in inflammatory forms of arthritis.20 There are two forms of corticosteroids: oral and injectable. Both forms are effective in relieving pain and swelling for many types of arthritis.1 2 3 4 5 6 11 12 13 14 16 18 21 22 23
Disease-modifying anti-rheumatic drugs (DMARDs)
DMARDs are medications that suppress inflammation and prevent damage to the joint.1 4 11 20 24 Currently, clinical treatment guidelines for RA recommend the initiation of DMARDs as soon as the diagnosis is confirmed. DMARDs do not have an immediate effect — relief is usually delayed. As a result, NSAIDs and corticosteroids are often used when initiating therapy with DMARDs.4 DMARDs are also used in the treatment of AS, PsA, and connective tissue disorders.2 5 7 16 18 21
Biologic response modifiers
Biologic response modifiers are the newest class of arthritis medication. Similar to DMARDs, biologic response modifiers suppress inflammation and help to prevent joint damage.20 Biologic response modifiers provide symptomatic control and functional improvement in patients for whom treatment with one or more DMARDS has failed,and they are often used in combination with DMARDS.11 20
"I live with a great deal of fear that this drug will stop working and others may not work or be available to me."
— Person living with rheumatoid arthritis
Arthritis-related prescriptions dispensed to people with arthritis
Prescriptions by arthritis type
In 2007, over 4 million prescriptions for NSAIDs were written in Canada for individuals with a diagnosis of arthritis—the largest number among all categories of arthritis-related prescriptions. Nearly one third (30%) of NSAID prescriptions for arthritis were written for people diagnosed with OA, 9% were written for those diagnosed with RA, connective tissues diseases and other inflammatory arthritis and the remaining 61% were written for other types of arthritis such as, joint derangements, polymyalgia rheumatica, synovitis, bursitis, and unspecified arthropathies. NSAIDs can irritate the lining of the stomach and GI system. Protective drugs are prescribed to reduce the risk of irritation. Most of the GI protective agent prescriptions were either written for people with OA or for people with any of the other arthritis conditions (40% and 53%, respectively).
DMARDs are also commonly used among individuals with arthritis with over 1 million prescriptions written for people with arthritis in 2007. The majority (over 70%) of the 1 million DMARDs prescriptions were written for individuals with a diagnosis of RA. Corticosteroids prescriptions (62%) were most commonly written for those with a diagnosis that fell in the other arthritis conditions category.
Over 90% of biologic response modifier prescriptions were written for individuals diagnosed with RA.
| Number of prescriptions written for individuals with a diagnosis of arthritis | Percentage of prescriptions written for individuals with specific arthritis conditions | |||||
|---|---|---|---|---|---|---|
| OA | RA | Connective tissue disorders | Other inflammatory arthritis | Other arthritis conditions | ||
| Source: Public Health Agency of Canada, using data from the Canadian Disease and Therapeutic Index (CDTI), IMS Health Canada. | ||||||
| NSAIDs | 4,165,700 | 30.0 | 4.5 | 0.6 | 3.9 | 61.3 |
| DMARDs | 1,101,230 | 0.9 | 72.2 | 9.9 | 5.7 | 8.0 |
| Corticosteroids | 908,230 | 13.1 | 12.6 | 8.2 | 2.0 | 61.8 |
| Biologic response modifiers | 149,610 | - | 90.1 | - | 2.5 | - |
| GI protective agents | 283,650 | 40.0 | 6.1 | 0.1 | 10.3 | 52.8 |
Table 7-1 - Text Equivalent
"If any of the new biologics had been available when I was in my twenties, I believe I would have been in much better shape. What these drugs do for people in the early stages of arthritis is just remarkable. The key is an early diagnosis and aggressive treatment".
— Person living with rheumatoid arthritis
Prescriptions by age and sex and over time
NSAIDs and GI protective agents
In 2007, more NSAID prescriptions were written for women than men with arthritis for all age groups with the exception of those between the ages of 15 and 34 years (Figure 7-1). The number of NSAID prescriptions peaked among men 45–54 years of age and among women aged 55–64 years, and then declined. These findings are in keeping with the fact that arthritis is more common among women and that the majority of individuals with arthritis are of working age.
Figure 7-1 - Text Equivalent
More GI protective agent prescriptions were written for men than women with arthritis, with the exception of those aged 45–54 years and 65–74 years (Figure 7-2). There was an increase in the number of prescriptions for GI protective agents for men up to age 64 years. Whereas, there was a sharp increase in GI protective agent prescriptions among women between the ages of 35 and 54 years, followed by a steady decline thereafter.
Best practice guidelines recommend that GI protective agents be prescribed to treat or prevent the complications associated with NSAIDs use among those who present with risk factors for GI problems (e.g. advanced age, multiple NSAIDs use or prior ulcer). While a lower number of GI prescriptions were written for people with arthritis compared to the number of NSAIDs prescriptions, it is not possible to assess the potential gap between guidelines and clinical practice without knowing the proportion of individuals that presented with risk factors for GI problems.
Figure 7-2 - Text Equivalent
The number of prescriptions written for NSAIDs declined over time among women and men (Figure 7-3). For women, the number of prescriptions written peaked in 2004, followed by a steep decline. The decline may have resulted from the withdrawal of Rofecoxib (a COX-2 selective NSAID) from the Canadian market in September 2004. COX-2 selective NSAIDs were specifically developed to help reduce GI complications and while successfully decreasing the risk of GI events, these agents have been associated with an increase in cardiovascular risks.12 The decline may have been a result of the shift from prescription to over-the-counter use of NSAIDs.25 7-3
Figure 7-3 - Text Equivalent
The number of GI protective agent prescriptions written for women and men increased greatly between 2004 and 2005, and 2005 and 2006, respectively (Figure 7-4). The sharp decrease among women between 2006 and 2007 is concerning because the number of NSAIDs prescriptions did not as sharply decrease during this time.
Figure 7-4 - Text Equivalent
DMARDs
Estimated total number of GI* protective agent prescriptions for arthritis, by sex and year, Canada, 2002–2007
DMARDs are the primary therapy recommended for RA. The number of DMARD prescriptions written for women with arthritis was higher than for men in all age groups (Figure 7-5). This finding reflects the fact that the forms of arthritis that require treatment with a DMARD (including RA) are more common among women than men. The peak number of DMARD prescriptions was among women aged 45–64 years, after which the number began to decline; men's prescriptions peaked between 55 and 64 years of age which is consistent with the fact that the majority of individuals with arthritis are of working age.
Figure 7-5 - Text Equivalent
The time trends for DMARDs prescriptions varied according to sex. The number of prescriptions written for women with arthritis increased between 2002 and 2007 while the number for men remained stable until 2006, followed by a decrease in 2007 (Figure 7-6). It is not clear why the pattern for men and women is so different.
Figure 7-6 - Text Equivalent
Corticosteroids
In every age group, the number of corticosteroid prescriptions (oral and injected combined) written for women with arthritis was greater than that for men (Figure 7-7) which is in keeping with the fact that arthritis is more common among women. The number of prescriptions written for women with arthritis increased with age.
Figure 7-7 - Text Equivalent
A similar trend in the number of corticosteroid prescriptions (oral and injected combined) was found among women and men: the number prescriptions written decreased between 2002 and 2004, followed by an increase from 2004 to 2006, and a subsequent decrease in 2007 (Figure 7-8).
Figure 7-8 - Text Equivalent
Biologic response modifiers
Women received a higher number of written prescriptions for biologic response modifiers than men (Figure 7-9). This is in keeping with the higher prevalence of inflammatory arthritis conditions (such as RA) among women. The number of prescriptions written for women increased with age until 64 years whereas the number decreased among men within the same age groups.
Figure 7-9 - Text Equivalent
The number of biologic response modifier prescriptions written for women increased sharply between both 2002 and 2003, and 2006 and 2007 (Figure 7-10). There was a sharp increase in biologic response modifier prescriptions between 2006 and 2007 for both men and women. These increases may in part be the result of changes to provincial formularies, which have increased their coverage of biologics response modifiers.
Figure 7-10 - Text Equivalent
Summary
- Five main types of drugs are used to treat arthritis: analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, disease modifying anti-rheumatic drugs and biologic response modifiers.
- While there has been a decrease in the use of non- steroidal anti-inflammatory drugs and corticosteroids, there has been an increase in the use of the newer drugs i.e., disease modifying anti-rheumatic drugs and biologics.
- In 2007, over 4 million prescriptions for non-steroidal anti-inflammatory drugs were written in Canada for individuals with a diagnosis of arthritis, 30% were written for people with osteoarthritis, 9% were for rheumatoid arthritis, connective tissue diseases and other inflammatory conditions and 61% were for other arthritis conditions.
- Over 1 million disease modifying anti-rheumatic drugs prescriptions were written for people with arthritis in 2007 and the majority (over 70%) were written for individuals with a diagnosis of rheumatoid arthritis.
- Close to a million corticosteroids prescriptions were written in 2007 and they were most commonly written for those with a diagnosis in the 'other arthritis' category (62%).
- In 2007, approximately 150,000 biologic response modifier prescriptions were written of which, 90% were for individuals diagnosed with rheumatoid arthritis.
- With the exception of corticosteroids, more arthritis- related drugs prescriptions were written for women than men and for those of working age than the other age groups.
1 Kasman N, Power J, Mamdani M, Badley E. Use of Medication. In: Badley E, Glazier R. (Eds.), Arthritis and related conditions in Ontario ICES Atlas. 2nd ed. Toronto, ON: Institute for Clinical Evaluative Sciences (ICES), 2004.
2 Bijlsma JW, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Prac Res Clin Rheumatol 2007;21(1):59–76.
3 Keith MP, Gilliland WR. Updates in the management of gout. Am J Med 2007;120(3):221–4.
4 Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63(24):2451–65.
5 The Arthritis Society. Psoriatic Arthritis – Know Your Options . Toronto, ON: The Arthritis Society, 2007. URL: www.arthritis.ca/programs%20and%20resources/publications/default.asp?s=1.
6 Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol 2006;2(5):252–61.
7 Alenius GM. Psoriatic arthritis-new insights give new options for treatment. Curr Med Chem 2007; 14(3):359–66.
8 Mader R, Keystone E. Optimizing treatment with biologics. J Rheumatol 2007;35(80 Supl):16–24.
9 Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;33(78 Suppl):4–11.
10 Pelletier JP, Martel-Pelletier J. DMOAD developments: present and future. Bull NYU Hosp Jt Dis 2007;65(3):242–8.
11 Badley EM, MacKay C. Care for People with Arthritis: Evidence and Best Practices . Toronto, ON: Arthritis Community Research & Evaluation Unit (ACREU) University Health Network, 2005.
12 Kidd BL, Langford RM, Wodehouse T. Arthritis and pain. Current approaches in the treatment of arthritic pain. Arthritis Res Ther 2007;9(3):214.
13 Moore SC, Desantis ER. Treatment of complications associated with systemic sclerosis. Am J Health Syst Pharm 2008;65(4):315–21.
14 Stummvoll GH. Current treatment options in systemic Sclerosis (Scleroderma). Acta Med Austriaca 2002;29(1):14–9.
15 Majithia V, Geraci SA. Rheumatoid Arthritis: Diagnosis and Management. Am J Med 2007; 120(11):936–9.
16 The Arthritis Society. Ankylosing Spondylitis – Know Your Options . Toronto, ON: The Arthritis Society, 2007. URL: www.arthritis.ca/pro-grams%20and%20resources/publications/default.asp?s=1.
17 Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Prac Res Clin Rheumatol 2006;20(3):401–17.
18 Jonsson R, Moen K, Vestrheum D, Szodoray P. Current issues in Sjögren's syndrome. Oral Dis 2002;8(3):130–40.
19 Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037–66.
20 The Arthritis Society. Consumer's Guide Arthritis Medications . Toronto, ON: The Arthritis Society, 2007. URL: www.arthritis.ca/local%20programs/ca/publications%20and%20resour-ces/publications/default.asp?s=1
21 Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005;140(2):205–12.
22 Pongratz D. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis). J Neurol 2006;253 Suppl 5:V64–5.
23 Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2006;18(3):236–41.
24 The Arthritis Society. Arthritis Best Practice Guidelines . Toronto, ON: The Arthritis Society, 2004. URL: www.arthritis.ca/programs%2and%20resources/getting%20a%20gripeducationalmaterials/default.asp?s=1.
25 Moore, N. Ibuprofen: a journey from prescription to over-the-counter use. J R Soc Med. 2007;100 Suppl 48:2-6.
[Previous] [Table of Contents] [Next]
To share this page just click on the social network icon of your choice.